Mutation in BRAF V600E: A Poor Prognostic Marker in Stage III Colon Cancers With Deficient MMR?

JAMA Oncol. 2017 Sep 1;3(9):1284-1285. doi: 10.1001/jamaoncol.2017.0262.

Authors

Sheik Emambux¹, Guillaume Mouillet², David Tougeron^{1

3}

Affiliations

¹ Department of Medical Oncology, Poitiers University Hospital, Poitiers, France.
² Methodology and Quality of Life in Oncology Unit, Besançon University Hospital, Besançon, France.
³ Department of Gastroenterology, Poitiers University Hospital, Poitiers, France.

PMID: 28617898
DOI: 10.1001/jamaoncol.2017.0262

No abstract available

Publication types

Comment

MeSH terms

Colonic Neoplasms*
DNA Mismatch Repair*
Humans
Mutation
Neoplasm Recurrence, Local
Prognosis
Proto-Oncogene Proteins B-raf / genetics
Proto-Oncogene Proteins p21(ras) / genetics
Randomized Controlled Trials as Topic

Substances

KRAS protein, human
BRAF protein, human
Proto-Oncogene Proteins B-raf
Proto-Oncogene Proteins p21(ras)